Clinuvel Pharm Ords (CLVLF) 1.5000 $CLVLF
Actinic (Solar) Keratosis Therapeutic Pipeline Review 2014 - Includes 14 Company Profiles and 22 Drug Profiles
M2 - Mon Apr 28, 2:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ncvwjt/actinic_solar) has announced the addition of the "Actinic (Solar) Keratosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Actinic (Solar) Keratosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Actinic (Solar) Keratosis and special features on late-stage and discontinued projects. Scope: - The report provides a snapshot of the global therapeutic landscape of Actinic (Solar) Keratosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Actinic (Solar) Keratosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Actinic (Solar) Keratosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved in Therapeutics Development: - Biofrontera AG - Galderma S.A. - LEO Pharma A/S - Meda AB - Clinuvel Pharmaceuticals Limited - Quest PharmaTech Inc. - G&E Herbal Biotechnology Co., Ltd. - Paloma Pharmaceuticals, Inc. - Digna Biotech, S.L. - Foamix Ltd. - Telormedix SA - Genextra S.p.a. - Novelix Pharmaceuticals, Inc. - Advancell Drug Profiles: - aminolevulinic acid hydrochloride - SRT-100 - afamelanotide - sotirimod - resiquimod - AK-3012 - DAC-0060 - AD-17137 - LEO-43204 - disitertide - SL-017 - TMX-202 - P-529 - CUV-9900 - ANs-40 - NVX-207 - ANS-401 - ANS-403 - imiquimod - Drug For Actinic Keratosis - DNA Repair Polypeptides - Ingenol Mebutate Analogs for Dermatology and Cancer For more information visit http://www.researchandmarkets.com/research/nc...inic_solar
Vitiligo - Pipeline Review, H2 2013
M2 - Fri Nov 08, 4:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/w62kjt/vitiligo) has announced the addition of the "Vitiligo - Pipeline Review, H2 2013" report to their offering. 'Vitiligo - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Vitiligo, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Vitiligo. This research is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Vitiligo. - A review of the Vitiligo products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Vitiligo pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Vitiligo. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Vitiligo pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Vitiligo Overview Therapeutics Development Companies Involved in Vitiligo Therapeutics Development Drug Profiles - afamelanotide - SWT-05104 - SWT-05105 - ACH-24 - ReliDerm-M - Sun-0597 - CD-07387 - simvastatin - Gene Therapy For Vitiligo And Melanoma Featured News & Press Releases Appendix Companies Mentioned - Ache Laboratorios Farmaceuticos S/A - Clinuvel Pharmaceuticals Limited - Galderma S.A. - Reliance Life Sciences Pvt. Ltd. - Switch Biotech Llc . - Sun Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/w62kjt/vitiligo
Actinic Keratosis - Pipeline Review, H2 2012
M2 - Fri Aug 02, 6:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s2gp3d/actinic_keratosis) has announced the addition of the "Actinic Keratosis - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for actinic keratosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for actinic keratosis. The information is built using data and information sourced from proprietary databases, company/university websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for actinic keratosis. - A review of the actinic keratosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the actinic keratosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for actinic keratosis. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding actinic keratosis pipeline depth and focus of Indication therapeutics. Key Topics Covered: List of Tables List of Figures Introduction Report Coverage Actinic Keratosis Overview Therapeutics Development An Overview of Pipeline Products for Actinic Keratosis Companies Involved in Actinic Keratosis Therapeutics Development Actinic Keratosis - Therapeutics Assessment Drug Profiles Featured News & Press Releases Appendix Companies Mentioned: - Almirall, S.A - Birken GmbH - Celtic Pharmaceutical Holdings L.P - Clinuvel Pharmaceuticals Limited - FunZyme BioTechnologies S.A - GliaMed, Inc - Meda AB - MediQuest Therapeutics, Inc - Moberg Derma AB - NexMed, Inc - Quest PharmaTech Inc - Telormedix SA For more information visit http://www.researchandmarkets.com/research/s2..._keratosis
SurModics Signs License Agreement with Clinuvel Pharmaceuticals
M2 - Sun Jun 16, 7:09AM CDT
SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced today that it has entered into a license agreement with Clinuvel Pharmaceuticals Limited of Melbourne, Australia. Under the agreement, the Company's SurModics Pharmaceuticals unit has licensed certain of its biodegradable polymer implant technology to Clinuvel for the treatment of sun-induced skin disorders. Terms of the agreement were not disclosed.
Actinic (Solar) Keratosis Therapeutic Pipeline Review 2014 - Includes 14 Company Profiles and 22 Drug Profiles
M2 - Mon Apr 28, 2:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ncvwjt/actinic_solar) has announced the addition of the "Actinic (Solar) Keratosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Actinic (Solar) Keratosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Actinic (Solar) Keratosis and special features on late-stage and discontinued projects. Scope: - The report provides a snapshot of the global therapeutic landscape of Actinic (Solar) Keratosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Actinic (Solar) Keratosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Actinic (Solar) Keratosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved in Therapeutics Development: - Biofrontera AG - Galderma S.A. - LEO Pharma A/S - Meda AB - Clinuvel Pharmaceuticals Limited - Quest PharmaTech Inc. - G&E Herbal Biotechnology Co., Ltd. - Paloma Pharmaceuticals, Inc. - Digna Biotech, S.L. - Foamix Ltd. - Telormedix SA - Genextra S.p.a. - Novelix Pharmaceuticals, Inc. - Advancell Drug Profiles: - aminolevulinic acid hydrochloride - SRT-100 - afamelanotide - sotirimod - resiquimod - AK-3012 - DAC-0060 - AD-17137 - LEO-43204 - disitertide - SL-017 - TMX-202 - P-529 - CUV-9900 - ANs-40 - NVX-207 - ANS-401 - ANS-403 - imiquimod - Drug For Actinic Keratosis - DNA Repair Polypeptides - Ingenol Mebutate Analogs for Dermatology and Cancer For more information visit http://www.researchandmarkets.com/research/nc...inic_solar
Vitiligo - Pipeline Review, H2 2013
M2 - Fri Nov 08, 4:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/w62kjt/vitiligo) has announced the addition of the "Vitiligo - Pipeline Review, H2 2013" report to their offering. 'Vitiligo - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Vitiligo, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Vitiligo. This research is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Vitiligo. - A review of the Vitiligo products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Vitiligo pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Vitiligo. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Vitiligo pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Vitiligo Overview Therapeutics Development Companies Involved in Vitiligo Therapeutics Development Drug Profiles - afamelanotide - SWT-05104 - SWT-05105 - ACH-24 - ReliDerm-M - Sun-0597 - CD-07387 - simvastatin - Gene Therapy For Vitiligo And Melanoma Featured News & Press Releases Appendix Companies Mentioned - Ache Laboratorios Farmaceuticos S/A - Clinuvel Pharmaceuticals Limited - Galderma S.A. - Reliance Life Sciences Pvt. Ltd. - Switch Biotech Llc . - Sun Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/w62kjt/vitiligo
Actinic Keratosis - Pipeline Review, H2 2012
M2 - Fri Aug 02, 6:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s2gp3d/actinic_keratosis) has announced the addition of the "Actinic Keratosis - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for actinic keratosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for actinic keratosis. The information is built using data and information sourced from proprietary databases, company/university websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for actinic keratosis. - A review of the actinic keratosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the actinic keratosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for actinic keratosis. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding actinic keratosis pipeline depth and focus of Indication therapeutics. Key Topics Covered: List of Tables List of Figures Introduction Report Coverage Actinic Keratosis Overview Therapeutics Development An Overview of Pipeline Products for Actinic Keratosis Companies Involved in Actinic Keratosis Therapeutics Development Actinic Keratosis - Therapeutics Assessment Drug Profiles Featured News & Press Releases Appendix Companies Mentioned: - Almirall, S.A - Birken GmbH - Celtic Pharmaceutical Holdings L.P - Clinuvel Pharmaceuticals Limited - FunZyme BioTechnologies S.A - GliaMed, Inc - Meda AB - MediQuest Therapeutics, Inc - Moberg Derma AB - NexMed, Inc - Quest PharmaTech Inc - Telormedix SA For more information visit http://www.researchandmarkets.com/research/s2..._keratosis
SurModics Signs License Agreement with Clinuvel Pharmaceuticals
M2 - Sun Jun 16, 7:09AM CDT
SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced today that it has entered into a license agreement with Clinuvel Pharmaceuticals Limited of Melbourne, Australia. Under the agreement, the Company's SurModics Pharmaceuticals unit has licensed certain of its biodegradable polymer implant technology to Clinuvel for the treatment of sun-induced skin disorders. Terms of the agreement were not disclosed.
